Agency for Science, Technology and Research

MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.

Nalagenetics is a health-tech company specializing in genetic testing aimed at improving healthcare outcomes. Established in 2016, the company partnered with the Indonesian health ministry to distribute genetic test kits in rural communities in Papua and West Papua. Their testing has uncovered significant genetic insights, such as identifying that 20% of leprosy patients in the region possess a gene linked to severe reactions to Dapsone, an important anti-leprosy medication. This discovery aids healthcare professionals in determining safe treatment options for affected patients. Nalagenetics also develops a personalized prescription platform that enhances prescription efficacy through genetic testing and information management, providing patients and healthcare decision-makers with tailored insights on interacting with healthcare technologies.

Sentient.io offers an AI & Data Cloud Platform that enables software developers to easily integrate AI capabilities into their applications. The platform provides access to curated datasets and pre-trained models via APIs, allowing for seamless embedding of AI algorithms.

AUM Biosciences, established in 2018 and headquartered in Singapore, is an oncology-focused biotechnology company. It specializes in the early-stage development of innovative, affordable medicines for the treatment of prevalent cancers, with a focus on those common in Asia. The company's platform leverages AI-augmented technology to discover and develop targeted cancer therapies based on genetic targets, aiming to accelerate drug development and improve patient access to effective treatments. AUM Biosciences serves research institutes, clinicians, and pharmaceutical companies, with a portfolio spanning breast, gastric, hepatocellular, head and neck, and prostate cancers.